Open Access

[Retracted] MicroRNA‑495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin‑like growth factor receptor‑1

  • Authors:
    • Ying Ye
    • Juhua Zhuang
    • Guangdong Wang
    • Saifei He
    • Suiliang Zhang
    • Guoyu Wang
    • Jing Ni
    • Jiening Wang
    • Wei Xia
  • View Affiliations

  • Published online on: June 9, 2022     https://doi.org/10.3892/etm.2022.11432
  • Article Number: 505
  • Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye Y, Zhuang J, Wang G, He S, Zhang S, Wang G, Ni J, Wang J and Xia W: [Retracted] MicroRNA‑495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin‑like growth factor receptor‑1. Exp Ther Med 24: 505, 2022
APA
Ye, Y., Zhuang, J., Wang, G., He, S., Zhang, S., Wang, G. ... Xia, W. (2022). [Retracted] MicroRNA‑495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin‑like growth factor receptor‑1. Experimental and Therapeutic Medicine, 24, 505. https://doi.org/10.3892/etm.2022.11432
MLA
Ye, Y., Zhuang, J., Wang, G., He, S., Zhang, S., Wang, G., Ni, J., Wang, J., Xia, W."[Retracted] MicroRNA‑495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin‑like growth factor receptor‑1". Experimental and Therapeutic Medicine 24.2 (2022): 505.
Chicago
Ye, Y., Zhuang, J., Wang, G., He, S., Zhang, S., Wang, G., Ni, J., Wang, J., Xia, W."[Retracted] MicroRNA‑495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin‑like growth factor receptor‑1". Experimental and Therapeutic Medicine 24, no. 2 (2022): 505. https://doi.org/10.3892/etm.2022.11432